JPMorgan lowered the firm’s price target on AnaptysBio to $28 from $30 and keeps a Neutral rating on the shares. The analyst updated the company’s model to include expenses and share count.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- 5 Stocks that Analysts Love in March 2024
- Wedbush upgrades AnaptysBio to Outperform into clinical catalysts
- AnaptysBio upgraded to Outperform from Neutral at Wedbush
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- AnaptysBio reports Q4 EPS ($1.59), consensus ($1.60)
